Results 51 to 60 of about 39,319 (333)

Choosing ibrutinib wisely [PDF]

Blood, 2018
In this issue of Blood , Bartlett et al share their experience with the use of ibrutinib in patients with relapsed or refractory follicular lymphoma (FL ...
openaire   +3 more sources

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]

, 2017
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core   +1 more source

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, J. Novák, V. Strugov, D. Gill, J. Gribben, Kevin Kwei, S. Dai, E. Hsu, J. Dean, I. Flinn   +15 more
semanticscholar   +1 more source

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses

Leukemia, 2023
Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly develops in the lymph node (LN) and creates a protective and immunosuppressive niche that facilitates tumor survival, proliferation and chemoresistance.
F. Araujo-Ayala, Cèlia Dobaño-López, J. G. Valero, F. Nadeu, F. Gava, Carla Faria, Marine Norlund, R. Morin, Pascale Bernes-Lasserre, N. Serrat, Heribert Playa-Albinyana, Rubén Giménez, E. Campo, J. Lagarde, A. López-Guillermo, E. Giné, D. Colomer, C. Bezombes, P. Pérez-Galán   +18 more
semanticscholar   +1 more source

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2019
BACKGROUND Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have ...
T. Shanafelt, X. V. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman   +20 more
semanticscholar   +1 more source

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib

British Journal of Haematology, 2023
Waldenström macroglobulinaemia (WM) is characterized by the presence of a MYD88L265P mutation. This mutation promotes growth and survival of malignant cells through Bruton tyrosine kinase (BTK) activation.
S. Sarosiek, J. Gustine, C. Flynn, Carly Leventoff, M. Little, Timothy P. White, K. Meid, S. Treon, J. Castillo   +8 more
semanticscholar   +1 more source

Cardiovascular Toxicities Associated With Ibrutinib

Journal of the American College of Cardiology, 2019
Ibrutinib has revolutionized treatment for several B-cell malignancies. However, a recent clinical trial where ibrutinib was used in a front-line setting showed increased mortality during treatment compared with conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directly assessed in the study.The purpose of this ...
Salem, Joe-Elie, Manouchehri, Ali, Bretagne, Marie, Lebrun-Vignes, Bénédicte, Groarke, John, Johnson, Douglas, Yang, Tao, Reddy, Nishitha, Funck-Brentano, Christian, Brown, Jennifer, Roden, Dan, Moslehi, Javid   +11 more
openaire   +5 more sources

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib

Molecules, 2022
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laboratory information on IBR is a prerequisite of constructing
Gellért Balázs Karvaly, István Vincze, Alexandra Balogh, Zoltán Köllő, Csaba Bödör, Barna Vásárhelyi   +5 more
openaire   +3 more sources

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources